Podcast: Ex-Hilleman CEO On COVID-19 Vaccine Heterologous Boosting, Endemic Disease
Regulators Face Tough Time
As more countries adopt heterologous boosting of COVID-19 vaccines in a bid to improve supplies and/or immunity while reducing side effects, vaccines expert and ex-Hilleman CEO Davinder Gill talks to Scrip in an audio interview on the challenges of the strategy and of the disease becoming endemic.
